Matrix Metalloproteinase and Tissue Inhibitor Expression in Atherosclerotic and Non-Atherosclerotic Thoracic Aortic Aneurysm  by Schmoker, J.D. et al.
Abstracts
Gregory L. Moneta, MD, Abstracts Section Editor
Matrix Metalloproteinase and Tissue Inhibitor Expression in Athero-
sclerotic and Non-Atherosclerotic Thoracic Aortic Aneurysm
Schmoker JD, McPartland KJ, Fellinger EK, et al. J Thorac Cardiovasc Surg
2007;133:155-61.
Conclusion: Tissue inhibitor/metalloproteinase phenotypes of ath-
erosclerotic thoracic aneurysms (TA) are similar to those of abdominal aortic
aneurysms (AAA).
Summary: It is felt an imbalance of the equilibrium between matrix
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) can contribute to the formation of an AAA. Whereas atheroscle-
rotic TAs have similar histologic features as AAAs, many TAs are not
atherosclerotic in origin and are characterized more by extensive cystic
medial necrosis rather than the chronic, inflammatory cell infiltrate more
commonly found in atherosclerotic aneurysms.
It is known altered expressions of MMPs and their TIMPs influence
formation of atherosclerotic aneurysms in the abdominal aorta. In this
study, the authors sought to determine the expression of MMPs and
TIMPs in both nonatherosclerotic and atherosclerotic TAs. Comparisons
were also made with a set of age-matched controls. MMP-2 and -9
activities were measured with antibody capture, and TIMP-1 and -2
levels were measured by enzyme-linked immunosorbent assay. There
were 24 atherosclerotic aneurysms studied, 63 nonatherosclerotic aneu-
rysms, and 17 controls. Gene expression was assessed with reverse
transcriptase polymerase chain reaction.
All data are expressed in nanograms per milligram of protein. MMP
levels in controls, atherosclerotic, and nonatherosclerotic groups were 80
7, 49 50, and 35 44, (P .002). In the atherosclerotic group, MMP-9
activity was greater than in the nonatherosclerotic group and controls (11.7
 15.7 vs 2.5 2.2 vs 1.7 1.9, P .001). In the control group, TIMP-1
and -2 levels were greater than in either aneurysm group. TIMP-1 levels
were 376 192 vs 234 233 vs 174 148 (P .003), and TIMP-2 levels
were 143  74 vs  13 vs 27  43 in the control, atherosclerotic, and
nonatherosclerotic groups, respectively (P  .001). MMP messenger RNA
was expressed to a greater degree in atherosclerotic aneurysms than in
controls.
Comment:Not surprisingly, MMP-9 levels were higher in atheroscle-
rotic TAs than in controls and nonatherosclerotic TAs. The authors also
noted regional differences in MMP activity levels, with ascending athero-
sclerotic TAs having higher total MMP-2 activity than descending athero-
sclerotic TAs. They postulate reduced MMP-2 activity and TIMP protein
gene expression in nonatherosclerotic TAs compared with controls may
reflect dysfunction of smooth muscle cells with respect to their ability to
compensate for age-related hemodynamic stresses.
Antithrombotic Therapy and Endovascular Stents Are Effective Treat-
ment for Blunt Carotid Injuries: Results From Long-Term Follow-up
Edwards NM, Fabian TC, Claridge JA. J Am Coll Surg 2007;204:1007-15.
Conclusions: In the long term, anticoagulation and antiplatelet ther-
apies are equally effective in preventing cerebral infarction after blunt carotid
injury (BCI). In patients with pseudoaneurysms or extensive dissections,
carotid stents appear to be safe and effective.
Summary: Heparin has traditionally been used to reduce stroke rates
after BCI, especially carotid dissection. Antiplatelet therapy (aspirin or
clopidogrel, or both) is now considered alternative therapy to anticoagula-
tion but does not have proven efficacy. About 13% of BCIs are associated
with pseudoaneurysms. Carotid stenting has been used for treatment of such
lesions. Results have been mixed, with both positive (J Trauma 2000;48:
470-2) and negative results (Arch Surg 2005;140:480-5). This article
sought to address the long-term efficacy of antiplatelet and anticoagulation
therapy, and carotid stents in the treatment of BCI.
The authors followed up consecutive patients treated for BCI at a single
trauma center from 1996 through 2005. Outcomes evaluated included
cerebral infarction, functional status, and angiographic evolution of the
lesion.
During the study period, 110 patients were diagnosed with 133
BCIs. Mortality was 26%, with 6% of the mortality directly attributed to
the BCI. Angiographic follow-up was available in 50 patients (67 inju-
ries) at a mean of 6 months after injury (range, 0.25 to 67 months). Of
these visualized injuries, 75% remained the same or improved. Clinical
follow-up was available in 55 of 81 patients (68%) who survived to
discharge. Mean follow-up was 34.4 months (range, 1 to 109 months).
Of the surviving patients, 44% were treated with antiplatelet therapy, 49%
with anticoagulation, and 7% were treated with both. There were no
episodes of cerebral infarction after discharge and no difference in
functional outcome based on the use of anticoagulant vs antiplatelet
therapy. A total of 22 endovascular stents were placed: 18 for pseudoan-
eurysm and four for extensive dissection. The mean follow-up of these
patients was 29.7 months (range, 3 to 94 months). No patients who
received a stent experienced periprocedural complications. One patient
with an associated brain injury had a cerebral infarct.
Comment: The data here are obviously incomplete and do not settle
the controversy of anticoagulant vs antiplatelet therapy for BCI. Either
therapy appears effective. Only a randomized trial will settle the issue. A
widely publicized previous study criticizing carotid stents for treatment of
pseudoaneurysms or dissections after BCI was published before widespread
use of antiplatelet therapy in conjunction with carotid stents. It may be that
the improved results with carotid stents in this report are because almost all
of the patients treated with carotid stents for BCI in this series were also
treated with antiplatelet therapy.
High-Density Lipoprotein and the Risk of Recurrent Venous
Thromboembolism
Eichinger S, Pecheniuk NM,Hron G, et al. Circulation 2007;115:1609-14.
Conclusion: High levels of apolipoprotein A1 and high-density li-
poprotein (HDL) decrease the risk of recurrent venous thromboembolism
(VTE).
Summary:HDL acts as a relative protector against atherosclerosis. The
authors sought to determine whether HDL levels also protect against
recurrent VTE. The study cohort comprised 772 patients with a first episode
of spontaneous VTE. The average follow-up was 48 months. The end point
was symptomatic recurrent VTE, which developed in 100 of the 772
patients. The authors then sought to evaluate levels of plasma lipoproteins in
recurrence of VTE. Apolipoproteins A1 and B were measured by immuno-
assay.
Patients with recurrent VTE had lower levels, mean  standard
deviation, of apolipoprotein A1 (1.12  0.22 vs 1.23  0.27 mg/mL, P
 .001). They had similar apolipoprotein B levels. Relative risk of
recurrence of VTE was 0.87 (95% confidence interval [CI], 0.80 to 0.94)
for each increase of 0.1 mg/mL of plasma apolipoprotein A1. Patients
with apolipoprotein AI levels in the lowest tertial (1.07 mg/mL) had a
relative risk of 0.46 (95% CI, 0.27 to 0.77) compared with the highest
tertial patients (apolipoprotein A1 1.30 mg/mL). Patients in the
lowest tertial of apolipoprotein A1 levels had a relative risk of 0.78 (95%
CI, 0.50 to 1.22) compared with the middle tertial patients (apolipopro-
tein A1 levels of 1.07 to 1.30 mg/mL). Nuclear magnetic resonance was
used to analyze levels of 10 major lipoprotein subclasses and HDL. There
was a strong trend for recurrence of VTE with low levels of HDL particles
and HDL cholesterol.
Comment: Apolipoprotein A1 is the major protein component of
HDL cholesterol. Given the prospective nature of this study, it provides
strong evidence for protection against risk of recurrent VTE by increased
levels of HDL cholesterol. Metabolism of HDL is complex, but it does
appear to have some antithrombotic properties. HDL can down-regulate
thrombin and act directly on endothelium to minimize peripheral throm-
botic reactions. Because women with VTE have higher levels of HDL than
men, the findings in the current study may partially explain the higher
recurrence rate for VTE in male vs female patients (N Engl J Med 2004;
350:2558-63).
Patient Fitness and Survival After Abdominal Aortic Aneurysm Repair
in Patients from the UK EVAR Trials
The EVAR Trial participants. Br J Surg 2007;94:709-16.
Conclusion: Endovascular repair has greatest benefit in the fittest
patients. There is no evidence that fitter patients benefit from open
surgery compared with endovascular repair of an abdominal aortic aneu-
rysm (AAA).
Summary: The authors sought to determine whether fitter patients with
large AAAs would have greater benefit from open rather than endovascular
repair. The authors used the customized probability index (CPI) in this study.
CPI is one of several preoperative fitness scoring systems that has been devel-
oped and validated. CPI evaluates measures of cardiovascular disease, treat-
ments for hypertension, respiratory dysfunction, renal dysfunction, and medi-
cation use, including -blockers and statins. Patients receive positive points for
indicators of poor fitness and negative points for indicators of better fitness.
Possible scores range from a –25 (good fitness) to57 (poor fitness).
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